“`html
Study Summary: Comparing Chemotherapy Cycles for Small-Cell Lung Cancer
Researchers compared the outcomes of patients with limited-stage small-cell lung cancer (LS-SCLC) who received either 6 cycles or 4-5 cycles of chemotherapy combined with thoracic radiotherapy (TRT).
Key Findings:
- Patients who received 6 cycles of chemotherapy showed significant improvement in overall survival (OS) and progression-free survival (PFS) compared to those who received 4-5 cycles.
- The two-year and five-year OS rates were higher in the 6 cycles group than in the 4-5 cycles group.
Practical Implications:
- Administering 6 cycles of chemotherapy combined with TRT may lead to notably enhanced survival for LS-SCLC patients.
- Physicians should consider the potential benefits of 6 cycles of chemotherapy when treating LS-SCLC patients.
“`
